Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials
Open Access
- 22 June 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 11 (1), 181-13
- https://doi.org/10.1186/1471-2334-11-181
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Prolonged β-Lactam Infusion for Gram-negative InfectionsThe Pediatric Infectious Disease Journal, 2011
- Outcome Reporting Among Drug Trials Registered in ClinicalTrials.govAnnals of Internal Medicine, 2010
- Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infectionsDiagnostic Microbiology and Infectious Disease, 2009
- Optimizing bactericidal exposure for β-lactams using prolonged and continuous infusions in the pediatric populationPediatric Blood & Cancer, 2009
- Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.Journal of Antimicrobial Chemotherapy, 2002
- Comparaison de deux schémas d'administration (continu ou discontinu) d'un antibiotique temps-dépendant : la TazocillinePathologie Biologie, 2001
- Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumoniaInternational Journal of Antimicrobial Agents, 2001
- Cost‐Effectiveness of Ceftazidime by Continuous Infusion versus Intermittent Infusion for Nosocomial PneumoniaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosisBritish Journal of Clinical Pharmacology, 2000
- Intermittent and continuous ceftazidime infusion for critically ill trauma patientsThe American Journal of Surgery, 2000